Quantitation of uronic acid precipitable by cetylpyridinium chloride (CPC) and electrophoretic separation of glycosaminoglycans were performed on sera from patients with chronic renal failure and compared to normal controls. Serum CPC-precipitable uronic acid (CpUA) levels in patients with renal failure were significantly higher (mean 13· 7 mg/L, range 7· 1-23' 6 mg/L) than normal controls (mean 9'6mg/L, range 5'1-13'9mg/L) due to increased concentrations of low sulphated chondroitin sulphate. A positive correlation between serum CpUA and creatinine was found in renal failure patients.
SUMMARY. Quantitation of uronic acid precipitable by cetylpyridinium chloride (CPC) and electrophoretic separation of glycosaminoglycans were performed on sera from patients with chronic renal failure and compared to normal controls. Serum CPC-precipitable uronic acid (CpUA) levels in patients with renal failure were significantly higher (mean 13· 7 mg/L, range 7· 1-23' 6 mg/L) than normal controls (mean 9'6mg/L, range 5'1-13'9mg/L) due to increased concentrations of low sulphated chondroitin sulphate. A positive correlation between serum CpUA and creatinine was found in renal failure patients.
Urine CpUA excretion was raised in renal failure patients compared to normal controls with an increased excretion of chondroitin sulphate (Ch-S) of reduced electrophoretic mobility. Heparan sulphate (HS), a major glycosaminoglycan in normal urine, was absent from the urine of these patients.
The possible origin of urine glycosaminoglycans and the role of the kidney in glycosaminoglycan metabolism are discussed.
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The origin of serum glycosaminoglycans (GAGs) is not clearly understood, but both connective tissue' and blood cells-have been suggested as possible sources. Uptake by the liver] or excretion by the kidney" are possible routes for the removal of GAGs from the circulation. However, reports in the literature differ as to the role and importance of the kidney in GAG metabolism.
Some studies support the hypothesis that urine GAGs originate from blood by glomerular filtration in normal individuals. Wessler! suggested that urine GAGs were likely to originate from blood since the major GAG in plasma and urine was chondroitin sulphate (Ch-S), and heparan sulphate (HS), another urine GAG, was also present in small amounts in plasma. A major urine GAG fraction was shown to correlate with hydroxyproline excretion by Poulsen" who suggested that this reflected connective tissue turnover. Laurent et 01. 7 have identified a hyaluronic acid fraction in the urine of normal individuals which was shown by gel filtration studies Correspondence: Mrs L Bower. 190 to be of low molecular weight (range 4000-12000), suggesting that this urinary GAG could have originated from blood by glomerular filtration. Patients with renal insufficiency were shown to have raised plasma GAGs by Friman et 01., 8 in agreement with the work of Warren? and Hallgren et 01. 10 Friman et 01. 8 also showed a strong positive correlation between plasma GAG and plasma creatinine concentrations which suggested that plasma GAG concentration depends on glomerular filtration rate. Unfortunately, urine GAGs were not investigated in the latter study.
Other reports in the literature have suggested that urine GAGs are unlikely to originate from serum GAGs in normal individuals. Erikson et 01. 11 compared serum and urine GAGs in cases of mucopolysaccharidoses, renal failure and normal subjects and showed that urine GAG excretion was independent of serum GAG concentration. Hata et 01. 12 showed that low sulphated Ch-S was a major component of normal serum but a minor component of normal urine. Qualitative analysis of normal urine GAGs 1 ] has shown that they are very different from normal serum GAGs. 14 
Shum et al.l~showed that the renal clearance of GAGs is very low compared to inulin.
If serum GAGs are excreted by the kidney then changes in the composition of serum and urine GAGs might be expected in patients with impaired renal function. A study of serum and urine GAGs in patients with renal failure compared to normal controls was undertaken to clarify the role of the kidney in GAG metabolism. 
MATERIALS AND METHODS

Materials
Samples
Fresh samples of normal human serum were obtained from 47 healthy blood donors (age 21-64 years) by courtesy of the SW Regional Blood Transfusion Service and stored at -20°C until analysed. Serum samples were obtained from 34 patients (age 18-88 years) with a clinical diagnosis of chronic renal failure (serum creatinine concentrations > 400 iLmol/L). Nine patients were receiving dialysis at the time of the study and in these cases all samples were collected immediately before dialysis. Twenty-four hour urine collections were obtained from five patients (age 36-57 years) with a clinical diagnosis of chronic renal failure and values for creatinine clearance in the range 2-11 mL/min. Control data were obtained from five age and sex matched healthy volunteers, mainly laboratory staff.
Isolation and analysis of serum glycosaminoglycans Serum GAGs were isolated using papain digestion and CPC precipitation. The GAG-CPC complexes were dissolved in sodium chloride and reprecipitated in ethanol as described by Bower et al," CPC-precipitable uronic acid (CpUA) was quantitated using the modified carbazole method of Bitter and Muir.!" Serum GAG fractions were separated using cellulose acetate electrophoresis in calcium acetate buffer followed by staining with Alcian Blue. 14 Serum urea and creatinine levels were assayed on an 'Astra-4' analyser (Beckman Instruments, High Wycombe, UK) using methods described by Finley et al. 1 ? Isolation and analysis of urine glycosaminoglycans Glycosaminoglycans were isolated from aliquots (5 mL) of urine by CPC precipitation followed by dissolution of the complex in sodium chloride and final precipitation in ethanol, according to the method of Manley et al. 13 Urinary CpUA was quantitated using the modified carbazole method of Bitter and Muir." Urine samples (50 mL) were concentrated by vacuum dialysis to a volume of 5 mL. After concentration the samples were papain digested and the GAGs precipitated with CPC prior to electrophoresis on cellulose acetate." The final dried precipitates were dissolved in distilled water (50 iLL).
Data analysis
Before statistical analysis the distribution of CpUA results in the control group was tested for goodness of fit to a normal distribution.'! The control data was shown to be normally distributed. Differences between and within groups were assessed using Student's r-test.!?
RESULTS
Serum CpUA concentrations
The serum CpUA concentrations in patients with renal failure compared to normal controls are shown in Fig. 1 . In the control group the mean serum CpUA levels in men (9'9mg/L, n=27) and in women (9' 3 mg/L, n = 20) were not significantly different (t= 1'25, 0·5>P>0·1). The mean serum CpUA concentration in the normal controls was 9· 6 mg/L, range 5· 1-13. 9 mg/L. A reference range of 6· 4-12' 8 mg/L (mean ± 2 standard deviations) was calculated for CpUA concentrations in the control group. Applying a correction factor of 2·5 to allow for the fact that standard chondroitin-4-sulphate (Ch-4-S) contains approximately 40% uronic acid gave a reference range for total serum GAGs of 16-32 mg/L. The mean CpUA concentration in patients with renal failure (13' 7 mg/L, range 7· 1-23 . 6 mg/L) was significantly higher than the control group (t=6'41, P<O·OOI). Serum CpUA levels in patients with renal failure plotted against serum creatinine are shown in Fig. 2 . Serum CpU A and creatinine showed a significant positive correlation (r=0'46, P<O·OI) whereas the correlation between urea and CpUA was not significant (r=0'085, P>0·5).
Urine CpUA excretion and electrophoretic separation of urine GAGs
The mean CpUA excretion in patients with renal failure (4'74 mg/24 h, range 2'46-8,40 mg124 h) was raised compared to normal controls (mean 2· 55 mg124 h, range I· 73-3' 27 mg124 h). Normal urine contained two alcian blue positive fractions which were identified as Ch-S (fast fraction) and HS (slow fraction) using enzyme digestion (Fig. 4 ). Electrophoretic separation of urine GAGs from patients with renal failure showed an intense alcian blue positive band of slower mobility than standard Ch-4-S and a haze of aldan blue staining material (Fig. 4) . All the GAGs present were
c d e f g chondroitinase ABC labile and not digested by heparitinase ( Fig. 4 ). There was no evidence for the presence of hyaluronic acid using Streptomyces hyaluronidase. The major alcian blue positive fraction in patients with renal failure was of similar electrophoretic mobility to HS but was unaffected by heparitinase digestion and totally destroyed by chondroitinase ABC.
DISCUSSION
The similarity of serum uronic acid levels between men and women in the control group agreed with previous reports." The mean total serum GAG concentration (24 mg/L) was higher than in other studies." However the work of Warren? on normal serum GAGs using laser nephelometry gave a mean value of 19· 4 mg/L which is comparable with the value reported here. The higher reference range in this study may be explained by the improved recovery of serum GAGs compared to earlier methods." The significantly higher levels of CpUA in the sera of patients with chronic renal failure compared to normal controls, and its positive correlation with serum creatinine was not unexpected as similar findings had been reported by Friman et al. 8 and Warren." These results support the hypothesis that diminished glomerular filtration rate leads to an accumulation of GAGs in serum. Chondroitin sulphate is a major GAG in both normal serum and normal urine which suggests that it may be excreted by glomerular filtration. However, although normally sulphated serum Ch-S has a molecular weight of approximately 37 100 and is not covalently bound to protein'? there is some evidence that it is unlikely to be freely filtered by the glomerulus because of its size and charge. IS The fact that electrophoretic studies showed the increase in serum GAGs in chronic renal failure to be limited to Fraction 2 was unexpected. The available evidence suggests that, in normal serum, this GAG is undersulphated Ch-S bound to protein with a molecular weight in excess of 100 000,12 is denatured by heat? and is probably excreted via the liver. 23 However small amounts of protein-free undersulphated Ch-S have been reported in normal serurrr" and there is one report of increased amounts of protein-free low sulphated Ch-S in a patient with renal failure. 8 The method used for the isolation of serum GAGs in the present study involved proteolysis of serum before CPC precipitation of GAGs thus precluding any studies of protein binding in the isolated GAGs.
Why this low sulphated Ch-S rather than normally sulphated Ch-S, which is a major GAG component of normal urine, is increased in the serum of patients with chronic renal failure is at present unexplained. The reported molecular weight of protein-free low sulphated Ch-S is in the range 2800_8000 12.22 which suggests it should be freely filtered by the glomerulus. The absence of reports of low sulphated Ch-S in normal urine raises the possibility that this GAG is normally filtered by the glomerulus and rapidly catabolized or sulphated by the renal tubules.
The increased urinary CpUA excretion in patients with chronic renal failure was unexpected and difficult to explain if urine GAGs are derived mainly from serum by glomerular filtration. The finding of Erickson et al," that serum GAGs of patients with Hunter's syndrome are similar to normal controls whereas the urine GAG excretion is greatly increased, is also inconsistent with the concept of urine GAGs being derived mainly from filtration of serum GAGs. This raises the possibility that part or all of the urine GAGs may be derived from renal tissue itself.
The most striking result of the electrophoretic and enzymatic studies of the urine GAGs in chronic renal failure was the total disappearance of HS and the reduction in Ch-S of normal electrophoretic mobility, both of which are major components of normal urine. The major urinary GAG component in patients with chronic renal failure had a mobility similar to that of HS but its electrophoretic characteristics and enzyme lability were identical to the serum GAG fraction, Fraction 2, which suggests that it is low sulphated Ch-S.
The origin of HS in normal urine is not clearly understood. There is very little detectable HS in normal human serum-" so urine HS is unlikely to be derived by simple glomerular filtration. The size and highly charged nature of HS would also be against glomerular filtration." However the HS content of both renal cortex and medulla is high? so it is possible that HS is actively synthesized by renal tissue and then excreted into the urine. This hypothesis would explain the disappearance of HS from the urine of patients with chronic renal failure. If the kidney is responsible for the production and secretion of HS in normal urine then it is tempting to speculate on its function. One possibility is that HS may have a role in inhibiting the formation of urinary calculi.
The ability of urine to inhibit formation of phosphate crystals was investigated by MacLagan and Anderson in the 1950s 26 who referred to this phenomenon as the 'protective colloid efficiency' and showed that one of the major contributors to this process was urinary 'mucopolysaccharide' . Unfortunately the identity of this urine GAG was not investigated further. Recently work by Baggio et alY has suggested a possible role for HS in inhibiting the formation of calcium oxalate calculi. These workers showed that erythrocyte GAG content correlated inversely with oxalate flux rate in stone formers and that HS promoted a significant fall in the rate of oxalate self exchange in vivo.
The decreased amounts of Ch-S of normal electrophoretic mobility in the urine of patients with chronic renal failure and the appearance of a major fraction with the characteristics of low sulphated Ch-S is difficult to explain. Chondroitin sulphate in normal urine has the same electrophoretic mobility as the fast Ch-S fraction in serum which has been identified as normal or oversulphated Ch-S. 14 The molecular size, charge and clearance of this GAG suggest that it is unlikely to be filtered by the glomerulus." Since Ch-S is only a minor component of renal tissue? its presence in urine cannot be explained unless the kidney possesses specific transport mechanisms. One possibility is that short chains of low sulphated Ch-S are normally filtered by the glomerulus and resulphated in the renal tubules, but there is no evidence to support this and it is difficult to think of any reason for such a mechanism to exist.
The unexpected findings of this study, particularly the apparent disappearance of HS from the urine in chronic renal failure, require further clarification. The role of the kidney in human GAG metabolism is clearly more complex than a simple mechanism for the excretion of serum GAGs. In particular, the purpose of the apparent addition of HS by the kidney to the urine of normal individuals deserves further investigation.
